Hongwei Xu
- Hematology top 2%
- Multiple Myeloma Research and Treatments 25
- Cancer Research top 10%
- MicroRNA in disease regulation 8
- Oncology top 10%
- Peptidase Inhibition and Analysis 7
- Pancreatic and Hepatic Oncology Research 4
- Molecular Biology top 10%
- Protein Degradation and Inhibitors 12
- Ubiquitin and proteasome pathways 8
- Histone Deacetylase Inhibitors Research 5
- Genetics top 10%
-
- Cancer Mechanisms and Therapy 6
- Co-authors
- Fenghuang ZhanGuido TricotYe YangJiliang XiaZhimin GuMohamed E. SalamaMaurizio ZangariWei Xiong
- Cited by
- HematologyCancer ResearchOncology
- Partner nations
- ChinaUnited StatesItaly
In The Last Decade
Hongwei Xu
64 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 120
- Hematology 384
- Cancer Research 249
- Oncology 396
- Molecular Biology 903
- Genetics 82
Countries citing papers authored by Hongwei Xu
This map shows the geographic impact of Hongwei Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hongwei Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hongwei Xu more than expected).
Fields of papers citing papers by Hongwei Xu
This network shows the impact of papers produced by Hongwei Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hongwei Xu. The network helps show where Hongwei Xu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hongwei Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 13 | |
| 5 | 2023 | 1 | |
| 6 | 2023 | 27 | |
| 7 | 2023 | 3 | |
| 8 | 2023 | 3 | |
| 9 | 2023 | 1 | |
| 10 | 2023 | 1 | |
| 11 | 2023 | 5 | |
| 12 | 2021 | 8 | |
| 13 | 2017 | 1 | |
| 14 | Geochemical characteristics and genesis of the Yanchang Formation terrestrial shale gas in the Yanchang exploration area | 2017 | 2 |
| 15 | 2015 | 37 | |
| 16 | 2015 | 87 | |
| 17 | 2014 | 35 | |
| 18 | 2013 | 57 | |
| 19 | 2012 | 1 | |
| 20 | The cytotoxicity of IL-24 gene-modified CIK cells to HL-60 cells. | 2009 | 1 |
About Hongwei Xu
Hongwei Xu is a scholar working on Hematology, Oncology and Cancer Research, having authored 75 papers that have together received 1.3k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (25 papers), Protein Degradation and Inhibitors (12 papers), Ubiquitin and proteasome pathways (8 papers), MicroRNA in disease regulation (8 papers), Peptidase Inhibition and Analysis (7 papers), Cancer Mechanisms and Therapy (6 papers), Histone Deacetylase Inhibitors Research (5 papers) and Pancreatic and Hepatic Oncology Research (4 papers). The work is most often cited by research in Hematology (384 citations), Cancer Research (249 citations) and Oncology (396 citations). Hongwei Xu has collaborated with scholars based in China, United States and Italy. Frequent co-authors include Fenghuang Zhan, Guido Tricot, Ye Yang, Jiliang Xia, Zhimin Gu, Mohamed E. Salama, Maurizio Zangari, Wei Xiong, Jumei Shi and Wen Zhou.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.